During a rocky week, The Dow
Procter & Gamble
Johnson & Johnson
Pfizer got some bad news from an FDA panel, which issued a report saying its neurodegenerative drug tafamidis should not be approved. Although the drug will still go before an advisory panel, the report is obviously bad news. The drug itself may not be such a major deal to the company -- the condition it is meant to treat only affects about 10,000 people in the entire world -- but the big risk for Pfizer has been its pipeline issues. The stock now yields a moderately high 4% dividend, in this case a sign of how concerned investors are about its ability to maintain earnings growth in the future.
Procter & Gamble has been having difficulties with its international operations lately. In April it announced that price cut mandates in Venezuela, weak economic performance in developed markets, and rising input costs would eat into its profits. This week, its CFO said the company has spent too much effort going after emerging-market growth, perhaps at the expense of market share in developed markets. P&G derives 20% of its sales from Western Europe, an area struggling under the weight of economic and financial turmoil.
An FDA advisory panel voted against recommending approving J&J's blood thinner Xarelto for treating acute coronary syndrome (coronary blood clots). A decision for Eliquis, a competing drug from Pfizer and Bristol-Myers Squibb
Pfizer, Procter & Gamble, and Johnson & Johnson lost to the market this week. But it's important for us to remember that it's the long term that really matters to us as investors. If you're looking for some intriguing stock ideas, The Motley Fool's chief investment officer picked his top stock for the year – it's a company that is revolutionizing commerce in rapidly developing Latin American economies. For a limited time, you can get instant access to the name of this company and a special report for free by clicking here.
Ilan Moscovitz doesn't own shares of any companies mentioned. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Procter & Gamble, Johnson & Johnson, and Pfizer. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Does a Strong Start Make 2018 a Sure Winner for Stocks?
Find out whether the so-called "January effect" is real.
Meet the 2018 Dogs of the Dow
Learn the basics of this simple dividend-investing strategy.
The Dow's Worst Day in 2017
Even with big gains, there were some scary times for the average.